Inflazome Ltd.

14 articles with Inflazome Ltd.

• Inflazome Announces Acquisition by Roche

  9/21/2020

  Inflazome is a pioneering inflammasome company developing orally available NLRP3 inflammasome inhibitors to address clinical unmet needs across a wide variety of inflammatory diseases

• FDA Grants Orphan Drug Designation for Inflazome’s Inzomelid for the Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)

  7/14/2020

  Inzomelid is a potent, selective, orally-available, brain-penetrant NLRP3 inflammasome inhibitor intended for treatment of debilitating inflammatory diseases

• Inzomelid completes Phase I studies and shows positive results in the treatment of Cryopyrin-Associated Periodic Syndrome (CAPS)

  3/26/2020

  Inflazome, the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, announces the successful completion of a Phase I study of Inzomelid, alongside positive results from a Cryopyrin-Associated Periodic Syndrome patient dosed with Inzomelid.

• Inflazome’s Somalix Demonstrates Positive Safety, Tolerability and Pharmacodynamic Profile in its Phase I Study

  2/27/2020

  Inflazome, the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, announces the successful completion of a Phase I study of its investigational drug, Somalix.

• Inflazome IP Portfolio Strengthened with Patents Granted in US and Europe

  1/13/2020

  Inflazome announces that the United States Patent and Trademark Office and the European Patent Office will grant the patent application WO 2016/131098 as US 10,538,487 on 21 January 2020 and EP 3,259,253 on 15 January 2020.

• 

  World Parkinson’s Day: How Science Is Battling the Disease

  4/11/2019

  April 11 is World Parkinson’s Day, designed to raise awareness of Parkinson’s disease. Parkinson’s is a progressive disease of the nervous system that affects movement.
• 

  Inflazome Funding From The Michael J. Fox Foundation Underlines Foundation Involvement in Research

  3/26/2019

  Foundations increasingly play a large role in funding basic science both domestically and internationally. Recently, The Michael J. Fox Foundation for Parkinson’s Research (MJFF) granted Dublin and Cambridge, UK-based Inflazome more than $1 million.

• Inflazome Receives Funding from The Michael J. Fox Foundation for Parkinson’s Research

  3/25/2019

  Funding in excess of US$1 million to support the development of a brain imaging probe for patient diagnosis and the clinical development of drugs to treat neurodegenerative diseases

• Inflazome Appoints Prof. Marco Colonna M.D. to Its Scientific Advisory Board

  2/18/2019

  Distinguished scientist with deep expertise in innate immunity and its role in neurodegenerative diseases

• 

  BioSpace Movers and Shakers for Dec. 3

  12/3/2018

  Biotechs and pharmas strengthened their leadership teams with these appointments. Find news from Mersana, Foamix, Allergan, and more.

• Inflazome Appoints Dr Thomas Jung as Chief Medical Officer

  11/29/2018

  Industry veteran clinician to lead the clinical development of Inflazome’s pioneering NLRP3 inflammasome inhibitors to treat inflammatory diseases

• Inflazome Completes €40m ($46m) Series B Financing to Develop NLRP3 Inflammasome Inhibitors to Clinical Proof-of-Concept

  11/19/2018

  Financing led by Forbion, with Longitude Capital and founding investors, Novartis Venture Fund and Fountain Healthcare Partners, also participating

• Inflazome: Validation of a New Target in Parkinson’s Disease

  10/31/2018

  Innovative research was funded by The Michael J. Fox Foundation for Parkinson’s Research and the Shake It Up Australia Foundation

• Inflazome Appoints Renowned Harvard Cardiologist to its Scientific Advisory Board

  1/4/2018

  Inflazome today announces the appointment of Prof. Paul Ridker to Inflazome’s Scientific Advisory Board.